A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients (18- <70 yrs) with CLL

Protocol No
ECOG-EA9161-CLL
Principal Investigator
Guru Subramanian Guru Murthy
Phase
III
Summary
This study is being done to answer the following question: What are the good and bad effects of a time limited administration of a targeted three drug treatment combination when compared with the more standard two drug treatment combination, which requires long-term, indefinite drug administration? Time limited administration means that you will only receive treatment for a specified period of time, rather than receiving treatment indefinitely. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your untreated CLL. The usual approach is defined as care most people get for CLL.
Description
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: